TCGA-L4-A4E6-01A-11R-A24H-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 67
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- IL6_JAK_STAT3_SIGNALING+0.460
- INFLAMMATORY_RESPONSE+0.450
- COAGULATION+0.410
- COMPLEMENT+0.370
- KRAS_SIGNALING_UP+0.370
- MYOGENESIS+0.370
- TNFA_SIGNALING_VIA_NFKB+0.370
- ALLOGRAFT_REJECTION+0.340
- KRAS_SIGNALING_DN+0.330
- ANGIOGENESIS+0.290
Top 10 suppressed
- MYC_TARGETS_V1-0.770
- E2F_TARGETS-0.730
- MYC_TARGETS_V2-0.720
- G2M_CHECKPOINT-0.670
- UNFOLDED_PROTEIN_RESPONSE-0.560
- DNA_REPAIR-0.550
- MTORC1_SIGNALING-0.530
- OXIDATIVE_PHOSPHORYLATION-0.530
- GLYCOLYSIS-0.480
- MITOTIC_SPINDLE-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-55-8619-01A-11R-2403-07 | — | cohortA1 | 0.971 |
| 2 | TCGA-38-A44F-01A-11R-A24H-07 | — | cohortA1 | 0.970 |
| 3 | TCGA-99-AA5R-01A-11R-A39D-07 | — | cohortA1 | 0.961 |
| 4 | TCGA-75-6203-01A-11R-1755-07 | — | cohortA1 | 0.945 |
| 5 | TCGA-56-8623-01A-11R-A28V-07 | — | cohortA1 | 0.943 |
| 6 | TCGA-98-A53C-01A-11R-A262-07 | — | cohortMD2 | 0.941 |
| 7 | TCGA-GM-A4E0-01A-12R-A266-07 | — | A | 0.940 |
| 8 | TCGA-55-8621-01A-11R-2403-07 | — | cohortA1 | 0.940 |
| 9 | TCGA-S2-AA1A-01A-12R-A39D-07 | — | cohortA1 | 0.933 |
| 10 | BS_R244Z0WX | pilocytic astrocytoma | — | 0.927 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.460 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.450 | Idelalisib | — uncovered |
| COAGULATION | 0.410 | Binimetinib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.370 | Inavolisib | — uncovered |
| MYOGENESIS | 0.370 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.370 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.330 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.290 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.260 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.250 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.170 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.120 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.110 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.090 | Temsirolimus | — uncovered |